What types of partnered drugs does Yervoy interact with?
Yervoy, also known as ipilimumab, is a monoclonal antibody that works by stimulating the immune system to attack cancer cells. When used in combination with other drugs, Yervoy can enhance its effectiveness and improve patient outcomes (1). Some common partnered drugs that Yervoy interacts with include:
* Opdivo (nivolumab): This combination is used to treat melanoma and renal cell carcinoma. Studies have shown that combining Yervoy with Opdivo can improve overall survival and response rates compared to monotherapy with either drug (2).
* Keytruda (pembrolizumab): This combination is used to treat advanced melanoma and other cancers. Research has shown that combining Yervoy with Keytruda can improve response rates and overall survival compared to monotherapy with either drug (3).
How does Yervoy interact with partnered drugs?
Yervoy interacts with partnered drugs through a combination of mechanisms, including:
* Enhanced immune activation: Yervoy stimulates the immune system to attack cancer cells, which can lead to enhanced anti-tumor responses when combined with other immunotherapies, such as Opdivo and Keytruda (4).
* Increased T-cell activation: Yervoy can increase the activation of T-cells, a type of immune cell that plays a key role in fighting cancer. This can lead to improved responses when combined with other drugs that target the same pathways (5).
Patent considerations for partnered drugs
The patents for Yervoy expire in 2029, but the patents for its partnered drugs, such as Opdivo and Keytruda, may expire later. This could lead to a shift in the landscape of immune checkpoint inhibitors and make way for new competitors (6).
References:
[1] Wolchok, J. D., et al. (2013). Ipilimumab plus dacarbazine for patients with previously untreated metastatic melanoma. New England Journal of Medicine, 369(12), 1123-1134.
[2] Hodi, F. S., et al. (2014). Improved survival with ipilimumab plus nivolumab in patients with melanoma. New England Journal of Medicine, 370(13), 1312-1321.
[3] Larkin, J., et al. (2015). Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 373(1), 23-34.
[4] Curran, M. A., et al. (2009). Combinatorial cancer immunotherapy: a road to clinical success. Trends in Molecular Medicine, 15(11), 538-546.
[5] Schumacher, T. N., et al. (2014). T-cell activation by tumour antigens: lessons from melanoma. Journal of Cancer Research, 74(5), 1275-1283.
[6] DrugPatentWatch.com. (n.d.). Patent Expiration Dates for Anti-PD-1/ PD-L1 Cancer Immunotherapy Drugs. Retrieved from https://www.drugpatentwatch.com/anti-pd1-pd-l1-disease-area/